Hasil Pencarian - Ludĕk Pour

Perbaiki Hasil
  1. 1
    Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse

    Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse oleh Jan Smetana, Jan Oppelt, Martin Štork, Luděk Pour, Petr Kuglík

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

    Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients oleh Lenka Sedlarikova, Lena Kubiczkova, Fedor Kryukov, Jana Pelcova, Zdenek Adam, Ludek Pour, Roman Hajek, Sabina Sevcikova

    Diterbitkan 2015-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data

    Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data oleh Sabina Sevcikova, Helena Paszekova, Lenka Besse, Lenka Sedlarikova, Veronika Kubaczkova, Martina Almasi, Ludek Pour, Roman Hajek

    Diterbitkan 2015-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.

    Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. oleh Karthick Raja Muthu Raja, Lenka Kubiczkova, Lucie Rihova, Martin Piskacek, Pavla Vsianska, Renata Hezova, Ludek Pour, Roman Hajek

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population

    Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population oleh Jiri Minarik, Ludek Pour, Vladimir Maisnar, Ivan Spicka, Alexandra Jungova, Tomas Jelinek, Lucie Brozova, Petra Krhovska, Vlastimil Scudla, Roman Hajek

    Diterbitkan 2019-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

    Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse oleh Ludek Pour, Sabina Sevcikova, Henrieta Greslikova, Renata Kupska, Petra Majkova, Lenka Zahradova, Viera Sandecka, Zdenek Adam, Marta Krejci, Petr Kuglik, Roman Hajek

    Diterbitkan 2014-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients

    LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients oleh Romana Bútová, Petra Vychytilová-Faltejsková, Jana Gregorová, Lenka Radová, Martina Almáši, Renata Bezděková, Lucie Brožová, Jiří Jarkovský, Zdeňka Knechtová, Martin Štork, Luděk Pour, Sabina Ševčíková

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.

    Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. oleh Lenka Besse, Lenka Sedlarikova, Fedor Kryukov, Jana Nekvindova, Lenka Radova, Ondrej Slaby, Petr Kuglik, Martina Almasi, Miroslav Penka, Marta Krejci, Zdenek Adam, Ludek Pour, Sabina Sevcikova, Roman Hajek

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance

    Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance oleh Lenka Kubiczkova, Fedor Kryukov, Ondrej Slaby, Elena Dementyeva, Jiri Jarkovsky, Jana Nekvindova, Lenka Radova, Henrieta Greslikova, Petr Kuglik, Eva Vetesnikova, Ludek Pour, Zdenek Adam, Sabina Sevcikova, Roman Hajek

    Diterbitkan 2014-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS

    ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS oleh Mehmut TURGUT, Roman HAJEK, Tomas JELÍNEK, Philippe MOREAU, Thomas MARTIN, Ludek POUR, Gabor MIKALA, Argiris SYMEONIDIS, Sara BRINGHEN, Andreea RAWLINGS, Marie Laure RISSE, Helgi VAN DE VELDE, Ivan SPICKA

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients

    Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients oleh Monika Vlachová, Lukáš Pečinka, Jana Gregorová, Lukáš Moráň, Tereza Růžičková, Petra Kovačovicová, Martina Almáši, Luděk Pour, Martin Štork, Roman Hájek, Tomáš Jelínek, Tereza Popková, Marek Večeřa, Josef Havel, Petr Vaňhara, Sabina Ševčíková

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

    P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS oleh Tereza Popková, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Petr Pavlíček, Tomas Jelínek, Marta Krejčí, Jan Straub, Vladimir Maisnar, Tereza Dekojová, Tomáš Pika, Jan Soukup, Lenka Pospíšilová, Roman Hájek

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas

    Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas oleh Martin Stork, Sabina Sevcikova, Tomas Jelinek, Jiri Minarik, Jakub Radocha, Tomas Pika, Lenka Pospisilova, Ivan Spicka, Jan Straub, Petr Pavlicek, Alexandra Jungova, Zdenka Knechtova, Viera Sandecka, Vladimir Maisnar, Roman Hajek, Ludek Pour

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

    Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis oleh Marcelo Capra, Thomas Martin, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios Dimopoulos

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma

    Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma oleh Monika Vlachová, Jana Gregorová, Petra Vychytilová-Faltejsková, Natalia Anna Gabło, Lenka Radová, Lenka Pospíšilová, Martina Almáši, Martin Štork, Zdeňka Knechtová, Jiří Minařík, Tereza Popková, Tomáš Jelínek, Roman Hájek, Luděk Pour, Lucie Říhová, Sabina Ševčíková

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

    ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study oleh Enrique M. Ocio, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, María-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul G. Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Luděk Pour

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease

    Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease oleh Martin Stork, Eva Ondrouskova, Michaela Bohunova, Ivanna Boichuk, Dominik Fric, Zdenek Adam, Marta Krejci, Viera Sandecka, Zdenka Knechtova, Lenka Radova, Zuzana Jelinkova, Tatana Adlerova, Milan Krticka, Vladimir Nekuda, Marek Borsky, Sabina Sevcikova, Marie Jarosova, Ludek Pour

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

    Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study oleh Luděk Pour, Monika Szarejko, Jelena Bila, Fredrik H. Schjesvold, Ivan Spicka, Vladimir Maisnar, Artur Jurczyszyn, Zhanet Grudeva-Popova, Roman Hájek, Ganna Usenko, Marcus Thuresson, Stefan Norin, Sara Jarefors, Nicolaas A. Bakker, Paul G. Richardson, Maria-Victoria Mateos

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS

    P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS oleh Enrique Maria Ocio San Miguel, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, Maria-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Ludek Pour

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

    Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma oleh Pieter Sonneveld, Sonja Zweegman, Michele Cavo, Kazem Nasserinejad, Annemiek Broijl, Rosella Troia, Ludek Pour, Sandra Croockewit, Paolo Corradini, Francesca Patriarca, Kalung Wu, Jolanda Droogendijk, Gerard Bos, Roman Hajek, Maria Teresa Petrucci, Paula Ypma, Nicholas Zojer, Monique C. Minnema, Mario Boccadoro

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: